A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy

Bassi Simona, Rabascio Cristina, Nassi Luca, Steffanoni Sara, Babic Aleksandra, Bertazzoni Paola, Gigli Federica, Antoniotti Pierluigi, Orlando Laura, Sammassimo Simona, Quarna Jessica, Negri Mara, Martinelli Giovanni

Research output: Contribution to journalArticle

Abstract

Pegfilgrastim has equivalent efficacy to daily G-CSF in enhancing neutrophil recovery after chemotherapy, but conclusive data concerning its use for peripheral blood stem cell (PBSC) mobilization are lacking. From 2003 to 2008 we used high-dose chemotherapy in 64 lymphoma patients. At mobilization chemotherapy (ESHAP) the first 26 patients used unconjugated G-CSF, while the remaining 38 patients received Pegfilgrastim. At the time of harvest 25 patients collected stem cells after the use of G-CSF and 36 in the Peg group. No statistical by significant differences were observed in median peripheral CD34+ cells mobilized (77μL versus 71μL) and in collected PBSC (12.3×106/kg versus 9.4×106/kg p=0.76). In the PEG group all patients collected the target PBSC with a single apheresis with a greater proportion of " optimal" mobilizers (83% versus 64%; p=0.05). In conclusion a single dose of Pegfilgrastim could be a valid alternative to unconjugated G-CSF to mobilize PBSC in lymphoma patients.

Original languageEnglish
Pages (from-to)321-326
Number of pages6
JournalTransfusion and Apheresis Science
Volume43
Issue number3
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Lymphoma
Granulocyte Colony-Stimulating Factor
Drug Therapy
Hematopoietic Stem Cell Mobilization
Blood Component Removal
Filgrastim
pegfilgrastim
Neutrophils
Stem Cells
Peripheral Blood Stem Cells

ASJC Scopus subject areas

  • Hematology

Cite this

A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. / Simona, Bassi; Cristina, Rabascio; Luca, Nassi; Sara, Steffanoni; Aleksandra, Babic; Paola, Bertazzoni; Federica, Gigli; Pierluigi, Antoniotti; Laura, Orlando; Simona, Sammassimo; Jessica, Quarna; Mara, Negri; Giovanni, Martinelli.

In: Transfusion and Apheresis Science, Vol. 43, No. 3, 12.2010, p. 321-326.

Research output: Contribution to journalArticle

@article{3b5fda3b882d49d8baeadbf06330d743,
title = "A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy",
abstract = "Pegfilgrastim has equivalent efficacy to daily G-CSF in enhancing neutrophil recovery after chemotherapy, but conclusive data concerning its use for peripheral blood stem cell (PBSC) mobilization are lacking. From 2003 to 2008 we used high-dose chemotherapy in 64 lymphoma patients. At mobilization chemotherapy (ESHAP) the first 26 patients used unconjugated G-CSF, while the remaining 38 patients received Pegfilgrastim. At the time of harvest 25 patients collected stem cells after the use of G-CSF and 36 in the Peg group. No statistical by significant differences were observed in median peripheral CD34+ cells mobilized (77μL versus 71μL) and in collected PBSC (12.3×106/kg versus 9.4×106/kg p=0.76). In the PEG group all patients collected the target PBSC with a single apheresis with a greater proportion of {"} optimal{"} mobilizers (83{\%} versus 64{\%}; p=0.05). In conclusion a single dose of Pegfilgrastim could be a valid alternative to unconjugated G-CSF to mobilize PBSC in lymphoma patients.",
author = "Bassi Simona and Rabascio Cristina and Nassi Luca and Steffanoni Sara and Babic Aleksandra and Bertazzoni Paola and Gigli Federica and Antoniotti Pierluigi and Orlando Laura and Sammassimo Simona and Quarna Jessica and Negri Mara and Martinelli Giovanni",
year = "2010",
month = "12",
doi = "10.1016/j.transci.2010.10.001",
language = "English",
volume = "43",
pages = "321--326",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy

AU - Simona, Bassi

AU - Cristina, Rabascio

AU - Luca, Nassi

AU - Sara, Steffanoni

AU - Aleksandra, Babic

AU - Paola, Bertazzoni

AU - Federica, Gigli

AU - Pierluigi, Antoniotti

AU - Laura, Orlando

AU - Simona, Sammassimo

AU - Jessica, Quarna

AU - Mara, Negri

AU - Giovanni, Martinelli

PY - 2010/12

Y1 - 2010/12

N2 - Pegfilgrastim has equivalent efficacy to daily G-CSF in enhancing neutrophil recovery after chemotherapy, but conclusive data concerning its use for peripheral blood stem cell (PBSC) mobilization are lacking. From 2003 to 2008 we used high-dose chemotherapy in 64 lymphoma patients. At mobilization chemotherapy (ESHAP) the first 26 patients used unconjugated G-CSF, while the remaining 38 patients received Pegfilgrastim. At the time of harvest 25 patients collected stem cells after the use of G-CSF and 36 in the Peg group. No statistical by significant differences were observed in median peripheral CD34+ cells mobilized (77μL versus 71μL) and in collected PBSC (12.3×106/kg versus 9.4×106/kg p=0.76). In the PEG group all patients collected the target PBSC with a single apheresis with a greater proportion of " optimal" mobilizers (83% versus 64%; p=0.05). In conclusion a single dose of Pegfilgrastim could be a valid alternative to unconjugated G-CSF to mobilize PBSC in lymphoma patients.

AB - Pegfilgrastim has equivalent efficacy to daily G-CSF in enhancing neutrophil recovery after chemotherapy, but conclusive data concerning its use for peripheral blood stem cell (PBSC) mobilization are lacking. From 2003 to 2008 we used high-dose chemotherapy in 64 lymphoma patients. At mobilization chemotherapy (ESHAP) the first 26 patients used unconjugated G-CSF, while the remaining 38 patients received Pegfilgrastim. At the time of harvest 25 patients collected stem cells after the use of G-CSF and 36 in the Peg group. No statistical by significant differences were observed in median peripheral CD34+ cells mobilized (77μL versus 71μL) and in collected PBSC (12.3×106/kg versus 9.4×106/kg p=0.76). In the PEG group all patients collected the target PBSC with a single apheresis with a greater proportion of " optimal" mobilizers (83% versus 64%; p=0.05). In conclusion a single dose of Pegfilgrastim could be a valid alternative to unconjugated G-CSF to mobilize PBSC in lymphoma patients.

UR - http://www.scopus.com/inward/record.url?scp=78649460876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649460876&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2010.10.001

DO - 10.1016/j.transci.2010.10.001

M3 - Article

C2 - 21036667

AN - SCOPUS:78649460876

VL - 43

SP - 321

EP - 326

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 3

ER -